XNAS · Healthcare · Biotechnology
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | 0.08 | 0.18 | +125.00% | $20.7M | ✅ Beat | +0.00% | +0.06% | — |
| 2026-05-19 | Q1 2026 | 0.06 | -0.10 | -266.67% | $17.7M | ❌ Miss | +0.00% | +0.98% | +2.03% |
| 2026-03-19 |
| Q4 2025 |
| 0.34 |
| 1.15 |
| +238.24% |
| $45.9M |
| ✅ Beat |
| -1.95% |
| +8.42% |
| +22.98% |
| 2025-11-10 | Q3 2025 | -0.08 | 0.07 | +187.50% | $20.0M | ✅ Beat | — | — | — |
| 2025-08-12 | Q2 2025 | -0.17 | -0.08 | +52.94% | $26.2M | ✅ Beat | +1.34% | +12.84% | +14.93% |
| 2025-02-26 | Q4 2024 | -0.08 | -0.05 | +37.50% | $18.8M | ✅ Beat | +2.09% | +7.05% | +1.65% |
| 2024-11-12 | Q3 2024 | -0.23 | -0.06 | +73.91% | $16.9M | ✅ Beat | +8.64% | +11.34% | +10.77% |
| 2024-05-13 | Q1 2024 | -0.25 | -0.09 | +64.00% | $14.5M | ✅ Beat | -1.98% | -5.01% | -9.81% |
Showing last 8 quarters.